IMC Chicago’s Sarepta Therapeutics SRPT Stock Holding History

IMC Chicago’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Sell	11,546 -2,349	-17%	-$44.4K	﹤0.01%	5641
2026 Q1	$302K	Sell	13,895 -29,397	-68%	-$569K	﹤0.01%	4580
2025 Q4	$932K	Buy	43,292 +17,214	+66%	+$363K	﹤0.01%	3030
2025 Q3	$503K	Buy	+26,078	New	+$465K	﹤0.01%	3176
2025 Q2	–	Sell	-17,985	Closed	-$767K	–	3578
2025 Q1	$1.15M	Buy	+17,985	New	+$1.89M	﹤0.01%	2185
2022 Q1	–	Sell	-15,193	Closed	-$1.37M	–	1245
2021 Q4	$1.37M	Buy	15,193 +268	+2%	+$22.9K	﹤0.01%	904
2021 Q3	$1.38M	Buy	14,925 +2,580	+21%	+$199K	﹤0.01%	918
2021 Q2	$960K	Buy	12,345 +577	+5%	+$43.7K	﹤0.01%	923
2021 Q1	$877K	Buy	+11,768	New	+$1.09M	﹤0.01%	873
2019 Q2	–	Sell	-11,864	Closed	-$1.44M	–	759
2019 Q1	$1.41M	Buy	+11,864	New	+$1.53M	0.01%	427

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

IMC Chicago's SRPT Position: Q2 2026 in Review

IMC Chicago reduced its Sarepta Therapeutics (SRPT) stake by 17% in Q2 2026, selling an estimated $44.4K and leaving 11,546 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #5641.

IMC Chicago first reported a position in SRPT in Q1 2019 and has held it in 10 quarters since. The position peaked at $1.41M in Q1 2019. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

IMC Chicago held 11,546 shares of Sarepta Therapeutics worth $207K as of Q2 2026.
IMC Chicago sold 2,349 Sarepta Therapeutics shares in Q2 2026, an estimated $44.4K.
Sarepta Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #5641 holding.
IMC Chicago first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 10 quarters since.
IMC Chicago's Sarepta Therapeutics position peaked at $1.41M in Q1 2019.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.